| answer text |
<p>The Medical Director of NHS England, Professor Steve Powis, and the Chief Medical
Officer, Professor Dame Sally Davies, have written to relevant clinicians to coincide
with the coming into force of the rescheduling of cannabis-based medicinal products.
The guidance in this letter, which signposts interim clinical advice commissioned
from the British Paediatric Neurology Association and the Royal College of Physicians,
is in line with normal clinical practice. The decision to prescribe cannabis-based
products for medicinal use will be made on a case-by-case basis, based on clinical
need and in-line with existing governance procedures for prescribing unlicensed medicines.</p><p>
</p><p>The Department has commissioned the National Institute for Health and Care
Excellence to produce clinical guidance by October 2019, which will update and replace
the interim advice.</p>
|
 |
